Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Sponsor: Ascidian Therapeutics, Inc
Summary
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Official title: ACDN-01-001: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinal ACDN-01 in Participants With ABCA4-related Retinopathy
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2024-06-11
Completion Date
2030-12-01
Last Updated
2025-12-02
Healthy Volunteers
No
Interventions
ACDN-01
ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
Locations (10)
University of San Francisco
San Francisco, California, United States
Vitreo Retinal Associates
Gainesville, Florida, United States
Bascom Palmer Eye Institute
Miami, Florida, United States
Wilmer Eye Institute at John Hopkins
Baltimore, Maryland, United States
Massachusetts Eye and Ear
Boston, Massachusetts, United States
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan, United States
Cincinnati Eye Institute
Cincinnati, Ohio, United States
Casey Eye Institute OHSU
Portland, Oregon, United States
Retina Foundation of the Southwest
Dallas, Texas, United States
Retina Consultants of Texas
Houston, Texas, United States